At the news
? BULLISHIMPACT 6/10 8-K filed Jun 17, 2026 at 16:36 ET
Corcept Therapeutics resubmitted its New Drug Application (NDA) to the FDA for relacorilant as a treatment for Cushing's syndrome, including additional analyses requested by the agency. The NDA is based on positive Phase III data from the GRACE and GRADIENT trials, and the company expects a six-month review. This represents a key step toward potential label expansion for a drug already approved in ovarian cancer, but approval is not guaranteed.
- NDA for relacorilant (Cushing's syndrome) resubmitted to FDA on June 17, 2026.
- Resubmission includes additional analyses of prior data as requested by the FDA.
- Corcept expects a six-month review cycle (~6 months).
- Positive data from pivotal GRACE trial, Phase III GRADIENT trial, and long-term extension study support the NDA.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access